LABCORP HOLDINGS INC. 8-K

What Happened
Labcorp Holdings Inc. announced that its Board of Directors appointed John H. Sampson, M.D., Ph.D., as a director effective February 9, 2026. The Board also assigned Dr. Sampson to the Quality and Compliance Committee. The appointment was disclosed in an 8-K filed February 9, 2026, and accompanied by a company press release (Exhibit 99.1).

Key Details

• Board appointment effective: February 9, 2026 (approved by the Board on February 6, 2026).
• Committee assignment: Quality and Compliance Committee.
• Compensation: Dr. Sampson will receive director pay under Labcorp’s standard director compensation program as described in the company’s 2025 proxy statement.
• Background: Dr. Sampson is vice chancellor for health affairs and dean at the University of Colorado Anschutz School of Medicine; previously held senior leadership roles at Duke University Health System; is a practicing neurosurgeon, a member of the National Academy of Medicine, and author of nearly 300 peer‑reviewed publications.

Why It Matters
This is a governance update that adds a senior medical and research leader to Labcorp’s Board and its Quality and Compliance Committee. For investors, the appointment may strengthen the Board’s clinical and research expertise relevant to Labcorp’s diagnostic and development services; there are no financial results or executive departures reported in this filing. The 8-K provides formal notice of the appointment and points to the press release for additional context.